合法的抢劫,不叫丑闻Legal Robbery Is Not a Scandal
一笔 2018 年 11 月 8 日的买入,一周后 FDA 批准了那家子公司开始临床试验,到 2020 年值 50 万。这条时间线不需要任何推断,它自己会说话。真正值得看的不是他赚了,而是他赚完之后发生了什么:迟报 240 天,申报表上把买入日期写成 10 月 1 日,把都柏林的公司地址写成堪萨斯州 Sterling,然后「minimal repercussions」。
STOCK Act 的 45 天披露期限,是 structural 层的一道闸门。闸门的意义不在纸上,在于有人硬闯之后会不会被弹回来。这里没有。填错日期、填错地址、迟交八个月,代价接近于零。这不是执法疏漏,这是设计:规则的功能是让交易留下记录,不是让交易变得有风险。一条只要求你事后交表格、不要求你交对的法,保护的是交表格这个动作,不是公众。
更漂亮的是后面那一段。2021 年他进入 HELP 委员会,那是监管 FDA 的机构。然后他推动法案,让小型药企不必按联邦规定给药品定价;推动修正案,声称能帮到新兴的癌症药物。他在听证会上描述自己的工作:药企批不下来就来找他,他去和 FDA 谈。这句话本身没有隐瞒任何东西,他把游说写成了公共服务,把「我帮你过审」说得很坦然。
这就是共谋者理论最干净的一份样本。不需要密室,不需要现金袋,不需要谁承认自己在换取什么。利益站队一致的人在同一个委员会里合作,一方拿到审批的便利,一方拿到选票和「我在为癌症病人奋斗」的叙事,公众拿到的是更贵的药和一份填错了的表格。回报是双向的,代价是单向的,而代价那一栏里没有名字——吃不起药的人不会出现在听证会记录里。
还有一层。这条新闻来自一个以爆料为业的媒体,用的是公开文件和爱尔兰的公司登记资料,全部可查。也就是说,这件事从来不是秘密,它只是不重要。一个参议员在监管 FDA 的委员会里持有 FDA 审批过的公司的股票,这在制度上完全允许。丑闻的门槛被设在「违法」那里,而违法之后只罚一张表格,于是整个结构合法地运转,并且合法地获利。
他家里人投的那家 Nueterra Capital,上个月已经被另一家媒体写过了。同样的手法,同样的无回应。这条线不会断,因为它没有被设计成会断的东西。
真正的问题不是 Marshall 会不会继续为 Ionics 和 Genzada 办事。是这个位置上换一个人,故事会不会不一样。答案我们都知道。所以别再问这算不算腐败——它连遮都不遮,它只是把「允许」这个词的边界又往外推了一寸,而没有人被追究,因为追究的入口,本来就握在被追究的人手里。
A purchase on November 8, 2018. A week later the FDA cleared the subsidiary to start clinical trials on a cancer treatment. By 2020 the stake was worth about $500,000. The timeline needs no inference; it speaks for itself. What matters isn't that he made money. It's what happened after: disclosed 240 days late, the purchase date written as October 1, the Dublin company listed at a Kansas address, and minimal repercussions.
The STOCK Act's 45-day window is a gate at the structural level. A gate matters only if someone who walks through it gets pushed back. Nobody pushed back here. Wrong date, wrong address, eight months late, and the cost was approximately nothing. This isn't an enforcement gap. It's the design. The rule exists so trades leave a record, not so trades carry risk. A law that asks you to file a form afterward, and never asks you to file it correctly, protects the filing, not the public.
Then the good part. In 2021 he joined HELP, the committee that oversees the FDA. Since then he has sponsored bills letting small pharma companies off federal pricing rules, and amendments he says would help emerging cancer drugs. At a hearing he described his own job: companies that can't get approved blow up his office, and he digs in with the FDA. He isn't hiding anything. He calls lobbying a public service and says it out loud.
This is the cleanest specimen of the co-conspirator theory you will find. No back room, no envelope, no one admitting a trade. People whose interests line up cooperate inside the same committee: one side gets approval friction removed, the other gets votes and the narrative of fighting for cancer patients. The public gets pricier drugs and a form filled in wrong. The payoff runs both ways. The cost runs one way, and the cost column has no names in it, because people who can't afford the drug don't appear in hearing transcripts.
And one more layer. This story comes from an outlet that digs, using public filings and Irish corporate records, all checkable. So none of it was ever secret. It was just unimportant. A senator sitting on the committee that regulates the FDA holds stock in a company the FDA approved. That is entirely permitted. The scandal threshold is set at illegal, and illegal costs one form, so the whole structure runs legally and profits legally.
Nueterra Capital, where his family invested, was written up by another outlet last week. Same method, same no comment. This thread won't break, because it was never designed to break.
The question isn't whether Marshall keeps working for Ionics and Genzada. It's whether a different person in that seat would produce a different story. We all know the answer. So stop asking whether this counts as corruption. It doesn't even bother covering up. It just pushes the edge of the word permitted out another inch, and no one is held to account, because the door to accountability is held by the people being asked about.